East Windsor, NJ—Sabinsa’s patented amla ingredient Saberry provides blood sugar support benefits, according to a 90-day, multicentric randomized open label trial. Saberry is the only Indian gooseberry extract standardized with beta glucogallin, a Gallotannin compound that Sabinsa says holds the key to health benefits obtained from Indian gooseberry. 

About the amla ingredient research

In subjects with hyperglycemia and BMI ranging from 27-35, Saberry was shown to significantly improve the key parameters of blood sugar levels, both fasting and post prandial, and lipid levels (LDL, VLDL and total cholesterol), according to a press release.

The study design used three arms with a total 126 subjects for comparing two dosages of Saberry supplementation (1g and 2g) with standard treatment group (metformin 500mg). Findings:

  • Both the dosages of Saberry showed improvement in glucose and lipid metabolism in a dose dependent manner
  • 2g showing 21.8% lowering of fasting blood sugar levels compared to 14.6% with a 1g dosage.
  • The 1g dose compared favorably with metformin results, while the 2g dose surpassed them.
  • Similar trends were noted with both dose regimen for total cholesterol, LDL, VLDL, and triglyceride levels.

Saberry is a self-affirmed GRAS ingredient that has been consumed as a dietary supplement for more than a decade. Sabinsa notes that it has an excellent taste profile and is water soluble. This, the company says, makes it a one-of-a-kind functional beverage ingredient.

More news from Sabinsa

Courtesy of Sabinsa

 

Sabinsa also shared that the company has expanded its intellectual property portfolio to more than 400 granted patents and more than 900 registered trademarks across the globe. The most recent granted patents are from Australia, Japan, Canada, Europe, and the U.S. Sabinsa’s  patent portfolio includes composition, use, and process patents.

Several of the patented flagship brands, BioPerine, Curcumin C3 Complex, LivLonga, LactoSpore, Sabroxy, and Curcumin C3 Reduct, are market leaders, according to the company. Many of the branded ingredients manufactured by the Sami-Sabinsa Group are used in dietary supplements, many have cosmetic applications, such as Proscalpin, LactoSporin, SabiWhite. Sabinsa continues to develop and market new patented ingredients such as Cirpusins, WithanAlpha, CurCousin, and Saberry.

“I’m extremely proud that the Sami-Sabinsa R&D team has demonstrated both scientific rigor and imagination in expanding my vision of using modern research to unlock new aspects of the wisdom of Ayurveda for so many decades,” said founder Dr. Muhammed Majeed, in a press release. “Our  innovation backed by science will continue to bring out trusted brands with  IP creation and protection, intertwined in our business model.”  

Read more about the patent portfolio here.